FDA Speeds Up Review Of Roche’s Immunotherapy Drug Tecentriq For Bladder Cancer – Counsel & Heal
Counsel & Heal |
FDA Speeds Up Review Of Roche's Immunotherapy Drug Tecentriq For Bladder Cancer
Counsel & Heal On January 2017, FDA has granted Tecentriq (atezolizumab) as a cancer immunotherapy drug. It has been evaluated as the first-line treatment option for people not eligible for cisplatin chemotherapy. The drug is also intended for people who are either … Roche Gets Priority Review for Immunotherapy Drug Tecentriq |
